2023 International Society for Vaccines (ISV) Annual Congress, October 22-25, Lausanne, Switzerland
2023 International Society for Vaccines (ISV) Annual Congress, October 22-25, Lausanne, Switzerland
批准号:
10754840
负责人:
DAVID B. WEINER
金额:
$0.5万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-22 至 2024-07-31
关键词:
2019-nCoVAcademiaAcinetobacter baumanniiAddressAdjuvantAfrican Swine Fever VirusAnimal ModelAntibody AffinityAntibody ResponseAntigensAreaAwardB-Lymphocyte EpitopesB-LymphocytesBone MarrowCOVID-19COVID-19 vaccineCancer VaccinesChildhoodClinicClinicalCommunicable DiseasesComplementComplexCongressesCountryCytotoxic T-LymphocytesDataDedicationsDengueDevelopmentDiseaseEmerging Communicable DiseasesEnsureEpitopesEventFoundationsGenerationsGovernmentHIV Envelope Protein gp120HIV-1HealthHealthcare SystemsHelper-Inducer T-LymphocyteHumanImmuneImmune responseImmunization ProgramsImmunologic MemoryImmunologyIncidenceIndustryInternationalKnowledgeLeadLearningLicensingMalariaMalaria VaccinesMalignant NeoplasmsMedicalMemory B-LymphocyteMentorsMessenger RNAMolecular ConformationMonoclonal AntibodiesMucosal ImmunityMucous MembraneMulti-Drug ResistanceMultiple Bacterial Drug ResistanceOralParasitesParticipantPersonsPhenotypePlasma CellsPlasmodium falciparumPoliciesPostdoctoral FellowPreparationPrizeRNA vaccineResearchRespiratory syncytial virus RSV F proteinsRoleSARS-CoV-2 infectionSafetyScientistSenior ScientistSiteSocietiesSpeedStreptococcus pyogenesStructureStudentsSurface AntigensSwitzerlandSystemT-LymphocyteT-cell receptor repertoireTechnologyTravelVaccine AntigenVaccine DesignVaccine ResearchVaccinesVariantViral reservoirVirus LatencyVirus-like particleZoonosescancer cellcareercareer developmentchronic infectionclinical developmentclinical implementationcollaborative environmentcostcost effectivedesigndoctoral studentexpectationfightinghealth care service organizationimprovedinfluenzavirusinsightlipid nanoparticlemalaria transmissionmanufacturemeetingsmembermicrobialmicroorganismmucosal vaccineneutralizing antibodynext generationnovel vaccinespathogenpeerposterspreventprogramsresponsescale upsevere COVID-19skillsstructural biologysymposiumtechnology platformtissue resident memory T celltransmission blockingvaccination strategyvaccine candidatevaccine effectivenessvaccine platformvaccinologyvirtualvolunteer
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract
The International Society for Vaccines (ISV) is a not-for-profit membership organization founded
in 1992 with members from 44 countries, holding annual congresses since 2007. With the ISV
Annual Congress, attended by member and non-member participants from 5 continents, the
Society aims to highlight the very latest ground-breaking developments in vaccine research,
manufacturing, clinical development and implementation, and safety. Plenary sessions are
devoted to current hot topics spanning diverse areas of vaccinology, including vaccines against
challenging targets, T-cell based vaccines, B cell memory establishment, structure-based
vaccine design, mucosal vaccines, and vaccines against emerging infectious diseases. The ISV
Congress, as the main comprehensive non-commercial vaccine meeting, strives to ensure
participation of speakers and delegates from a diverse background (academic, industry,
government, and foundations). Breakout sessions include topics related to adjuvant
mechanisms, One Health, vaccines against zoonotic infections, and next generation vaccines.
Renowned invited speakers in these fields have been and will be invited to set the stage for
each of the plenary topics, complemented with oral presentations selected from the submitted
abstracts. The program will also provide a forum for the next generation of scientists who are
active in the vaccinology field, to present their data in oral or poster presentations, discuss with
peers and senior scientists, and advance their careers, be it in academia, industry, or
government. ISV’s Bright Sparks in Vaccinology competition acknowledges student and postdoc
presentations in parallel sessions of the oral program to support the participation and careers of
next generation vaccinologists. To strengthen their professional advancements, the ISV
Congress, building on its long-standing commitment to mentoring, dedicate a session to career
development opportunities, bringing together junior and senior scientists in an interactive
atmosphere. To stimulate the participation of young scientists, which has always been
successful in the past, the ISV has a policy of inexpensive registration rates for PhD students
and provides Travel Awards to selected junior scientists (based upon abstract submission and
review for quality) to help defray costs of in-person and virtual participation. Prizes for best
presentations or oral abstracts and poster abstracts are a high priority of the ISV Officers, who
volunteer to review and rank all presentations during the ongoing conference to select winners
and runners up based on abstract quality and presentation skills, and present award certificates
to the prize winners.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10589586
-
项目类别:
-
资助金额:$72.69万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Administrative Core
-
批准号:10328139
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Rapid, single-dose coronavirus vaccines via DNA-launched nanoparticles and genetic adjuvants for durable anti-coronavirus immunity
-
批准号:10328141
-
项目类别:
-
资助金额:$110.71万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Synthetic DNA-launched and adjuvanted Env immunogens for HIV
-
批准号:10589585
-
项目类别:
-
资助金额:$449.79万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo
-
批准号:10589587
-
项目类别:
-
资助金额:$142.76万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
-
批准号:10459450
-
项目类别:
-
资助金额:$97.92万
-
财政年份:2019
-
负责人:DAVID B. WEINER
-
依托单位:
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
-
批准号:10004562
-
项目类别:
-
资助金额:$115.33万
-
财政年份:2019
-
负责人:DAVID B. WEINER
-
依托单位:
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
-
批准号:10228693
-
项目类别:
-
资助金额:$95.06万
-
财政年份:2019
-
负责人:DAVID B. WEINER
-
依托单位:
Administration
-
批准号:9261462
-
项目类别:
-
资助金额:$21.39万
-
财政年份:2017
-
负责人:DAVID B. WEINER
-
依托单位:
Multivalent DNA vaccine-mediated protection against Tuberculosis
-
批准号:10297846
-
项目类别:
-
资助金额:$86.53万
-
财政年份:2017
-
负责人:DAVID B. WEINER
-
依托单位:
Multivalent DNA vaccine-mediated protection against Tuberculosis
-
批准号:10054982
-
项目类别:
-
资助金额:$90.84万
-
财政年份:2017
-
负责人:DAVID B. WEINER
-
依托单位:
Synthetic DNA & Novel Env Vaccine for HIV
-
批准号:9024416
-
项目类别:
-
资助金额:$342.45万
-
财政年份:2015
-
负责人:DAVID B. WEINER
-
依托单位:
Synthetic DNA & Novel Env Vaccine for HIV
-
批准号:9261455
-
项目类别:
-
资助金额:$333.75万
-
财政年份:2015
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8721834
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8317646
-
项目类别:
-
资助金额:$111.31万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8525084
-
项目类别:
-
资助金额:$54.8万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8143485
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:9352656
-
项目类别:
-
资助金额:$10.75万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8017652
-
项目类别:
-
资助金额:$47.65万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Training in Vaccine & Immune Therapeutics
-
批准号:7503022
-
项目类别:
-
资助金额:$19.41万
-
财政年份:2008
-
负责人:DAVID B. WEINER
-
依托单位:
海外基金